Powered by

NeuroRx Receives Notice of Allowance from USPTO for a Formulation for the Treatment of Post-Traumatic Stress Disorder

Nov 04, 2020 - PR Newswire

PR Newswire

NeuroRx, Inc. today announced that it has received a notice of patent allowance from the United States Patent and Trademark Office (USPTO) covering a formulation for the treatment of post-traumatic stress disorder (PTSD), a condition according to the NIH that affects annually 3.6% or about 10-13 million people in the United States alone, of these, 37% can be classified as having severe PTSD, which significantly impairs their lives.  

The allowance is based on US P...